CLOUDR GROUP LTD. risk profile
66 Stretched several inputs deteriorating together
Measured 1 September 2026 from H3L's filed statements. Recomputed nightly.
66 (Stretched), driven by Leverage and coverage at 95, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 93 | Acute | Stable | Drawdown from the 52-week high — 65.4% |
| Operating pressure | 48 | Elevated | Worsening | Costs outgrowing revenue — +4.7 percentage points |
| Cash conversion | 91 | Acute | Stable | Capital spending against operating cash — 2.27x |
| Leverage and coverage | 95 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 55 | Elevated | Stable | Revenue-growth gap against peers — -60.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for CLOUDR GROUP LTD.